Depression and pegylated interferon-based hepatitis C treatment

References

• Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States. 1988–1994. N Engl J Med. 1999;341(8):556–562.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis C Fact Sheet. 2011. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed February 8, 2012.
   Google Scholar
• Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8–32.
   PubMed Web of Science ®Google Scholar
• Kotenko SV Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4(1):69–77.
   PubMed Web of Science ®Google Scholar
• Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4(1):63–68.
   PubMed Web of Science ®Google Scholar
• Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev. 1999;79(1):1–71.
   PubMed Web of Science ®Google Scholar
• Kiecolt-Glacer JK, Glacer R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res. 2002;53(4):873–876.
   Web of Science ®Google Scholar
• Leonard BE. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25(4):757–780.
   Web of Science ®Google Scholar
• Cooney JM, Dinan TG. Type II (glucocorticoid) receptors mediate fast-feedback inhibition of the hypothalamic-pituitary-adrenal axis in man. Life Sci. 1996;59(23):1981–1988.
   Web of Science ®Google Scholar
• Ramamoorthy S, Ramamoorthy JD, Prasad PD, et al. Regulation of the human serotonin transporter by interleukin 1-beta. Biochem Biophys Res Commun. 1995;216(2):560–567.
   Web of Science ®Google Scholar
• Abe S, Hori T, Suzuki T, et al. Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem Res. 1999;24(3):359–363.
   Web of Science ®Google Scholar
• Kugaya A, Kagaya A, Uchitomi Y, et al. Effect of interferon-alpha on DOI-induced wet-dog shakes in rats. J Neural Transm. 1996;103(8–9):947–955.
   Web of Science ®Google Scholar
• Fujigaki S, Saito K, Sekikawa K, et al. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an interferon-Y independent mechanism. Eur J Immunol. 2001;31(8):2313–2318.
   Web of Science ®Google Scholar
• Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Risk for depression during interferon-alpha treatment is affected by the serotonin transport polymorphism. Biol Psychiatry. 2009;65(4):344–348.
   Web of Science ®Google Scholar
• Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon alpha based immunotherapy are related to interferon alpha induced changes in the serotonergic system. J Clin Psycopharmacol. 2002;22(1):86–90.
   PubMed Web of Science ®Google Scholar
• Maes M, Verkerk R, Bonaccorso S, et al. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci. 2002;71(16):1837.
   Web of Science ®Google Scholar
• Wu HQ, Guidetti P, Goodman JH, et al. Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo. Neuroscience. 2000;97(2):243–251.
   Web of Science ®Google Scholar
• Okuda S, Nishiyama N, Saito H, Katsuki H. 3-hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem. 1998;70(1):299–307.
   PubMed Web of Science ®Google Scholar
• Orlikov AB, Prakhye IB, Ryzov IV, et al. Kynurenine in blood, plasma and DST in patients with endogenous anxiety and endogenous depression. Biol Psychiatry. 1994;36(2):97–102.
   Web of Science ®Google Scholar
• Mangoni A. The “kynurenine shunt” and depression. Adv Biochem Psychopharmacol. 1974;11(0):293–298.
   Google Scholar
• Issa F, Kirch DG, Gerhardt GA, et al. A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: II. Correlations with psychopathology. Psychiatry Res. 1994;52(3):251–258.
   Web of Science ®Google Scholar
• Maes M, Meltzer H. The serotonin hypothesis of major depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology. New York, NY: Raven Press; 1995:933–944.
   Google Scholar
• McIntyre N. Familial LCAT deficiency and fish eye disease. J Inherit Metab Dis. 1988;11 Suppl 1:45–56.
   Google Scholar
• Van der Vliet A, Bast A. Effects of oxidative stress on receptors and signal transmission. Chem Biol Interact. 1992;85(2–3):95–116.
   Web of Science ®Google Scholar
• Bilici M, Efe H, Koroglu MA, et al. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord. 2001;64(1):43–51.
   PubMed Web of Science ®Google Scholar
• Maes M, Bonaccorso S, Marino V et al. Treatment with interferonalpha of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry. 2001;6(4):475–480.
   Web of Science ®Google Scholar
• Comai S, Cavalletto L, Chemello L, et al. Effects of Peg-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C. Pharmacol Res. 2011;63(1):85–92.
   Web of Science ®Google Scholar
• Zignego MC, Cozzi A, Carpenedo R, et al. HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment. Dig Liver Dis. 2007;39 Suppl 1: S107–S111.
   Google Scholar
• Sockalingam S, Links PS, Abbey SE. Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. J Viral Hepat. 2011;18(3):153–160.
   Web of Science ®Google Scholar
• Rasenack J, Zeuzem S, Feinman VS, et al. Peginterferon alpha-2a improves HR-QOL outcomes compared with unmodified interferon alpha-2a in patients with chronic hepatitis C. Pharmacoeconomics. 2003;21(5):341–349.
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52(3):425–432.
   PubMed Web of Science ®Google Scholar
• Kraus MR, Schafer A, Csef H, Scheurlen M. Psychiatric side effects of pegylated interferon alpha-2b as compared to conventional interferon alpha-2b in patients with chronic hepatitis C. World J Gastroenterol. 2005:11(12):1769–1774.
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy RK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–982.
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358(9286):958–965.
   PubMed Web of Science ®Google Scholar
• Yasuda S, Miyata K. Interferon alfacon-1(Advaferon): a novel synthetic interferon for the treatment of hepatitis C, its pharmacological and clinical profile. Nippon Yakurigaku Zasshi. 2002;120(6):421–426.
   Google Scholar
• Yao GB, Fu XX, Tian GS, et al. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2000;15(10):1165–1170.
   Web of Science ®Google Scholar
• Melian EB, Plosker GL. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs. 2001:61(11):1661–1691.
   PubMed Web of Science ®Google Scholar
• Sjogren MH, Sjorgen R, Lyons MF, et al. Antiviral response to of HCV genotype -1 to consensus interferon and ribavirin, compared to pegy-lated interferon and ribavirin. Dig Dis Sci. 2007;52(6):1540–1547.
   Web of Science ®Google Scholar
• Zacks S, Beavers K, Theodore D, et al. Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol. 2006;40(3):220–224.
   Web of Science ®Google Scholar
• Hilsabeck RC, Malek-Ahmadi P. Neurobehavioral correlates of chronic hepatitis C. J Psychopathol BehavAssess. 2004;26:203–210.
   Web of Science ®Google Scholar
• Evon DM, Simpson KM, Esserman D, et al. Barriers to accessing care in patients with chronic hepatitis C: the impact of depression. Aliment Pharmacol Ther. 2010;32(9):1163–1173.
   PubMed Web of Science ®Google Scholar
• Randolff LS. The CES-D scale: a self-report depression scale for research in the general population. Applied Psycological Measurement. 1977;1:385–401.
   Google Scholar
• Clark CH, Mahoney JS, Clark DJ, et al. Screening for depression in a hepatitis C population: the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D). J Advanced Nurs. 2002;40(3):361–369.
   PubMed Web of Science ®Google Scholar
• Phillips FH, Prebis M, Grumbeck C, et al. Effects of recognizing depression with a standardized questionnaire (CES-D) versus patient reporting of depression after a single-standardized question on the outcomes of treatment for hepatitis C with pegylated interferon-a-2b and ribavirin. Eur J Gastroenterol Hepatol. 2010;22(12):1435–1442.
   Web of Science ®Google Scholar
• TanakaY, Nagaki M, Tomita E, et al. Psychoneurological symptoms during interferon therapy in patients with chronic hepatitis: prospective study on predictive use of Cornell Medical Index and electroencephalogram. Liver Int. 2004;24(5):407–412.
   Web of Science ®Google Scholar
• Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7(9):942–947.
   PubMed Web of Science ®Google Scholar
• Neri S, Bertino G, Petralia A, at al. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon a and ribavirin. J Clin Gastroenterol. 2010;44(9):210–217.
   Web of Science ®Google Scholar
• Fontana RJ, Kronfol Z, Lindsay KL, et al. Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol. 2008;103(11):2766–2775.
   Web of Science ®Google Scholar
• Kronfol Z, Litman HJ, Back-Madruga C, et al. No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. J Affect Disord. 2011;129(1–3):205–212.
   Web of Science ®Google Scholar
• Leutscher PD, Lagging M, Buhl MR. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 2010;52(2):430–435.
   Web of Science ®Google Scholar
• Evon D, Ramcharran D, Belle SH, Terrault NA, Fontana RJ, Fried MW. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol. 2009:104(12):2949–2958.
   Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.
   PubMed Web of Science ®Google Scholar
• Lotrich FE, Loftis JM, Ferrell RE, et al. IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferonalpha therapy. J Interferon Cytokine Res. 2011;31(3):331–336.
   Web of Science ®Google Scholar
• Kristiansen MG, Lochen ML, Gutteberg TJ, et al. Total and cause specific mortality rates in a prospective study of community-acquired hepatitis C virus infection in northern Norway. J Viral Hepat. 2011;18(4):237–244.
   Web of Science ®Google Scholar
• Ademmer K, Beutel M, Bretzel R, et al. Suicidal ideation with IFN-a and ribavirin in a patient with hepatitis C. Psychosomatics. 2001;42(4):365–367.
   PubMed Web of Science ®Google Scholar
• Sockalingan S, Balderson K. Major depressive episode with psychotic features induced by pegylated interferon alpha-2b and ribavirin treatment. Int Clin Psycopharmacol. 2005;20(5):289–290.
   Web of Science ®Google Scholar
• Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willenbring M. Suicidal ideation during interferon-a2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry. 2004;26(3):237–240.
   PubMed Web of Science ®Google Scholar
• Alvarez-Uria G, Day JN, Nasir AJ, et al. Factors associated with treatment failure of patients with psychiatric disease and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int. 2009;29(7):1051–1055.
   Web of Science ®Google Scholar
• Kraus MR, Schäfer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon alpha. N Engl J Med. 2001;345(5):375–376.
   PubMed Web of Science ®Google Scholar
• Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002;63(3):194–198.
   PubMed Web of Science ®Google Scholar
• Kraus MR, Schafer A, Schottker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomized, doubleblind, placebo-controlled study. Gut. 2007;57(4):531–536.
   Web of Science ®Google Scholar
• Morasco BJ, Loftis JM, Indest DW, et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a doubleblind, placebo-controlled trial. Psychosomatics. 2010;51(5):401–408.
   Web of Science ®Google Scholar
• Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high dose interferon alpha. N Engl J Med. 2001;344(13):961–966.
   PubMed Web of Science ®Google Scholar
• Raison CL, Woolwine BJ, Demetrashvili MF. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007;25(10):1163–1174.
   PubMed Web of Science ®Google Scholar
• Raison CL, Demetrashvili M, Carupon L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19(2):105–123.
   PubMed Web of Science ®Google Scholar
• Kraus MR, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving alpha-2b therapy. J Clin Psychiatry. 2003;64(6):708–714.
   PubMed Web of Science ®Google Scholar
• Kraus MR, Schafer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat. 2005;12(1):96–100.
   Web of Science ®Google Scholar
• Diez-Quevedo C, Masnou H, Planas R, et al. Prophylactic treatment with escitalopram of pegylated interferon alpha-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(4):522–528.
   PubMed Web of Science ®Google Scholar
• Yoshida K. Milnacipran in the treatment of elderly depressed patients including a case of interferon-induced depression. Int J Psych Clin Pract. 2003;7 Suppl 1:S19–S21.
   Google Scholar
• Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alpha and depression. Hepatology. 2000;31(6):1207–1211.
   PubMed Web of Science ®Google Scholar
• Crone C, Gabriel GM, Wise TN. Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleve Clin J Med. 2004;71 Suppl 3:S27–S32.
   Google Scholar
• Nickel T, Sonntag A, Backmund M, et al. Depression during therapy with interferon alpha-how long should antidepressant treatment last? Pharmacopsychiatry. 2005;38(2):102–104.
   Web of Science ®Google Scholar
• Lotrich F. Management of psychiatric disease in hepatitis C treatment candidates. Curr Hepat Rep. 2010;9(2):113–118.
   Google Scholar
• Rifflet H, Vuillemin E, Oberti F, et al. Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha. Gastroenterol Clin Biol. 1998;22(3):353–357.
   Google Scholar
• Gould RA, Ball S, Kaspi SP, et al. Prevalence and correlates of anger attacks: a two site study. J Affect Disord. 1996;39(1):31–38.
   PubMed Web of Science ®Google Scholar
• Huckans M, Mitchell A, Pavawalla S, et al. The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia. Antivir Ther. 2010;15(1):111–119.
   Web of Science ®Google Scholar
• Koh LK, Greenspan FS, Yeo PP. Interferon-a induced thyroid dysfunction: three clinical presentations and review of the literature. Thyroid. 1997;7(6):891–896.
   Web of Science ®Google Scholar
• Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003;13(6):547–551.
   Web of Science ®Google Scholar
• Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol. 1994;89(3):399–403.
   Web of Science ®Google Scholar
• Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alpha therapy. Hepatology. 1997;26(1):206–210.
   Web of Science ®Google Scholar
• Costelloe SJ, Wassef N, Schulzt J, et al. Thyroid dysfunction in a UK hepatitis C population treated with interferon-a and ribavirin combination therapy. Clin Endocrinol (Oxf). 2010;73(2):249–256.
   Web of Science ®Google Scholar
• Carella C, Mazziotti G, Amato G, et al. Interferon-alpha related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metabol. 2004;89(8):3656–3661.
   PubMed Web of Science ®Google Scholar
• Sato K, Miyakawa M, Demura H. Reversible, extremely severe hypothyroidism in a patient with chronic hepatitis C treated with interferonalpha. Thyroid. 1996;6(3):249–252.
   Web of Science ®Google Scholar
• Rao M. Depression in the physically ill. Prim Psychiatry. 2008;15(9):44–50.
   Google Scholar
• Turner EH, Blackwell AD. 5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotonin. Med Hypotheses. 2005;65(1):138–144.
   Web of Science ®Google Scholar
• Quarantini LC, Bressan RA, Galvao B, et al. Incidence of psychiatric side effects during pegylated interferon retreatment in nonresponder hepatitis C virus-infected patients. Liver Int. 2007;27(8):1098–1102.
   Web of Science ®Google Scholar
• Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in “difficult to treat” psychiatric patients with pegylated interferonalpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46(4):991–998.
   Google Scholar
• Yu ML, Dai CY, Lee LP, et al. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy. Antiviral Ther. 2006;11(8):1015–1019.
   Web of Science ®Google Scholar
• Wichers MC, Koek GH, Robaeys G, et al. IDO and interferon- alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2005;10(6):538–544.
   Web of Science ®Google Scholar
• Beratis S, Katrivanou A, Georgiou S, et al. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment. J Psychosom Res. 2005;58(1):15–18.
   Web of Science ®Google Scholar
• Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry. 2003;25(1):34–38.
   PubMed Web of Science ®Google Scholar
• Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. Hepatology. 2003;37(2):443–451.
   PubMed Web of Science ®Google Scholar
• Castera L, Zigante F, Bastie A, et al. Incidence of interferon alpha-induced depression in patients with chronic hepatitis C. Hepatology. 2002;35(4):978–979.
   PubMed Web of Science ®Google Scholar
• Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002;72(3):237–241.
   Web of Science ®Google Scholar
• Miyaoka H, Otsubo T, Kamijima K, et al. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry. 1999;156(7):1120.
   Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Eng J Med. 1998;339(21):1485–1492.
   PubMed Web of Science ®Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Eng J Med. 1998;339(21):1493–1499.
   Web of Science ®Google Scholar
• Nozaki O, Takagi C, Takaoka K, et al. Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: an overview of cases in Japan. Psychiatry Clin Neurosci. 1997;51(4):175–180.
   Web of Science ®Google Scholar
• Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol. 1996;24(1):38–47.
   PubMed Web of Science ®Google Scholar
• Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alpha-interferon therapy for chronic viral hepatitis. J Hepatol. 1994;21(2):241–243.
   Web of Science ®Google Scholar